Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | PHASE1 | COMPLETED | 30 | — | — | Sep 1, 2013 | Nov 1, 2017 | Sep 9, 2020 | 5 | United States |
The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with weekly nab-paclitaxel
| Arm | Type | Description |
|---|---|---|
| Vanctictumab (OMP-18R5) | EXPERIMENTAL | Vantictumab will be administered by intravenous (IV) infusion. |
| Nab-Paclitaxel | EXPERIMENTAL | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | EXPERIMENTAL | Gemcitabine will be administered by intravenous (IV) infusion. |
| Name | Type | Description |
|---|---|---|
| Vantictumab | DRUG | Administered intravenous (IV) infusion. |
| Nab-Paclitaxel | DRUG | Nab-Paclitaxel will be administered by intravenous (IV) infusion. |
| Gemcitabine | DRUG | Gemcitabine will be administered by intravenous (IV) infusion. |
Inclusion Criteria: * Signed Informed Consent Form * Age ≥18 years * Histologically documented Stage IV ductal adenocarcinoma of the pancreas * Availability of tumor tissue, either archival FFPE or obtained at study entry through fresh biopsy * ECOG performance status of 0 or 1 * Adequate hematolog...